<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03925636</url>
  </required_header>
  <id_info>
    <org_study_id>15858</org_study_id>
    <nct_id>NCT03925636</nct_id>
  </id_info>
  <brief_title>Specific Carbohydrate Diet for Clostridium Difficile</brief_title>
  <acronym>SCD_cDiff</acronym>
  <official_title>Treatment With the Specific Carbohydrate Diet for Children With Clostridium Difficile Colonization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>David Suskind</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pacific Northwest National Laboratory</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are doing this research study to answer questions about a nutritional
      therapy called the Specific Carbohydrate Diet (SCD) for children with active Clostridium
      Difficile Infection.

      For this study, the investigators will be looking to determine:

        1. Is SCD effective for the treatment for Clostridium Difficile Colonization?

        2. Is the SCD well tolerated?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to determine the tolerability and potential efficacy of dietary
      therapy, the Specific Carbohydrate Diet (SCD), in pediatric patients with persistent antigen
      positivity due to C. difficile colonization with minimally active symptomatology. The goal of
      this pilot study is to gather preliminary data for a future treatment controlled trial of SCD
      versus standard medical therapy.

      This is a single center, open labelled study designed to determine tolerability, preliminary
      safety and potential efficacy in pediatric patients with persistent C. difficile colonization
      with minimally active symptomatology. The study patients will be recruited from Seattle
      Children's Gastroenterology and Infectious Disease clinic.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 8, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with negative C. difficile stool</measure>
    <time_frame>12 weeks</time_frame>
    <description>Stool is analyzed for C. difficile antigen and toxin by enzyme-linked immunosorbent assay (EIA). Samples that are antigen positive and toxin negative by EIA screen will be analyzed by the more sensitive polymerase chain reaction amplification (PCR) assay to detect C. difficile toxin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants able to maintain the specific carbohydrate diet</measure>
    <time_frame>4 weeks</time_frame>
    <description>Diet diaries are reviewed to ascertain compliance to diet. Questionnaires are reviewed to determine barriers to implementing the diet.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <condition>Diet Modification</condition>
  <arm_group>
    <arm_group_label>Dietary therapy for C. difficile colonization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dietary therapy intervention for this arm is the Specific Carbohydrate Diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Specific Carbohydrate Diet</intervention_name>
    <description>The diet removes all grains such as wheat, barley, corn, rice, and most dairy products (except yogurt fermented for 24 hours and cheese aged for grater than 30 days). The diet mainly consists of meat, fruits, vegetables, nuts, oils, and honey.</description>
    <arm_group_label>Dietary therapy for C. difficile colonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Children and adolescents eighteen months old to twenty one years old

          2. Diagnosis of C. difficile based upon stool antigen and toxin

          3. Minimally active symptomatology based upon

               1. 4 or less stools per day

               2. No evidence of dehydration

               3. No evidence of bandemia or hypoalbuminemia on screening labs

          4. Parent/guardian and child must be able to comprehend the consent and assent

          5. Parent/guardian and participant must be able to attend study visits at baseline, and
             weeks +2, +4, +8, +12.

          6. Patient must not have had antibiotic treatment directed at C. difficile for at least 1
             week.

        Exclusion Criteria:

          1. Severe symptoms

               1. Abdominal pain that interrupts or inhibits normal activity

               2. Fever

               3. Vomiting

               4. Blood in stool

          2. Clinical signs of coexisting acute systemic illnesses (meningitis, sepsis, pneumonia),
             immunodeficiency, underlying severe chronic diseases, and cystic fibrosis

          3. Tobacco, alcohol or illicit drug abuse

          4. Currently taking antibiotics at time of enrollment

          5. Malnutrition as judged by the ratio of weight to height,

          6. Clinical signs of dehydration(CD score&gt;0)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David L Suskind, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seattle Children's Hospital and The University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mason E Nuding</last_name>
    <phone>206-987-0055</phone>
    <email>mason.nuding@seattlechildrens.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Research Coordinator</last_name>
    <phone>206-987-2521</phone>
    <email>giresearch@seattlechildrens.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mason E Nuding</last_name>
      <phone>206-987-0055</phone>
      <email>mason.nuding@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Clinical Research Coordinator</last_name>
      <phone>206-987-2521</phone>
      <email>giresearch@seattlechidlrens.org</email>
    </contact_backup>
    <investigator>
      <last_name>David L Suskind, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/30826445</url>
    <description>Case Series of dietary therapy for recurrent c. difficile and colonization</description>
  </link>
  <reference>
    <citation>Suskind DL, Wahbeh G, Gregory N, Vendettuoli H, Christie D. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr. 2014 Jan;58(1):87-91. doi: 10.1097/MPG.0000000000000103.</citation>
    <PMID>24048168</PMID>
  </reference>
  <reference>
    <citation>Suskind DL, Lee D, Solan P, Wahbeh G, Hayden H, Brittnacher M, Nuding M, Miller S. Dietary therapy for clostridium difficile colonization: A case series. Anaerobe. 2019 Jun;57:1-3. doi: 10.1016/j.anaerobe.2019.02.016. Epub 2019 Feb 28.</citation>
    <PMID>30826445</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 19, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Seattle Children's Hospital</investigator_affiliation>
    <investigator_full_name>David Suskind</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Specific Carbohydrate Diet</keyword>
  <keyword>Clostridium Difficile Infection</keyword>
  <keyword>Clostridium Difficile</keyword>
  <keyword>cDiff</keyword>
  <keyword>Diet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Not discussed</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/36/NCT03925636/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

